- Home
- PETS vs BMEA Comparison
PETS vs BMEA Comparison
Compare PETS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- BMEA
- Stock Information
- Founded
- PETS 1996
- BMEA 2017
- Country
- PETS United States
- BMEA United States
- Employees
- PETS N/A
- BMEA N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- BMEA Health Care
- Exchange
- PETS Nasdaq
- BMEA Nasdaq
- Market Cap
- PETS 62.8M
- BMEA 65.8M
- IPO Year
- PETS N/A
- BMEA 2021
- Fundamental
- Price
- PETS $3.62
- BMEA $1.63
- Analyst Decision
- PETS Sell
- BMEA Strong Buy
- Analyst Count
- PETS 2
- BMEA 11
- Target Price
- PETS $3.35
- BMEA $27.60
- AVG Volume (30 Days)
- PETS 135.2K
- BMEA 696.5K
- Earning Date
- PETS 06-10-2025
- BMEA 05-05-2025
- Dividend Yield
- PETS N/A
- BMEA N/A
- EPS Growth
- PETS N/A
- BMEA N/A
- EPS
- PETS 0.02
- BMEA N/A
- Revenue
- PETS $247,010,000.00
- BMEA N/A
- Revenue This Year
- PETS N/A
- BMEA N/A
- Revenue Next Year
- PETS N/A
- BMEA N/A
- P/E Ratio
- PETS $213.02
- BMEA N/A
- Revenue Growth
- PETS N/A
- BMEA N/A
- 52 Week Low
- PETS $2.90
- BMEA $1.53
- 52 Week High
- PETS $6.85
- BMEA $13.43
- Technical
- Relative Strength Index (RSI)
- PETS 53.72
- BMEA 37.94
- Support Level
- PETS $3.26
- BMEA $1.61
- Resistance Level
- PETS $3.74
- BMEA $2.30
- Average True Range (ATR)
- PETS 0.14
- BMEA 0.21
- MACD
- PETS 0.06
- BMEA -0.01
- Stochastic Oscillator
- PETS 80.95
- BMEA 3.11
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.